Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer

Annals of Surgical Oncology

Volumn 19, Issue 4, 2012, Pages 1326-1333

  Sehouli, Jalid ^a   Papanikolaou, G ^a   Braicu, E I ^a   Pietzner, K ^a   Neuhaus, P ^b   Fotopoulou, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER RECONSTRUCTION; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; EMERGENCY CARE; FEASIBILITY STUDY; FEMALE; FISTULA; FOLLOW UP; HUMAN; INTESTINE PERFORATION; MORBIDITY; OVARY CANCER; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND HEALING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEASIBILITY STUDIES; FEMALE; HUMANS; INTESTINAL OBSTRUCTION; INTESTINAL PERFORATION; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WOUND HEALING;

EID: 84862505537     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2134-0     Document Type: Article

References (44)

1. Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control. 2011;18:31-43.
2. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer. 2008;44:2350-6.
3. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902-8. (Pubitemid 47123154)
4. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230-8.
5. Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Daraï E. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Res. 2010;30:4743-7.
6. Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE 4th, Straughn JM Jr. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol. 2009;114:424-6.
7. Chéreau E, Stefanescu D, Selle F, Rouzier R, Daraï E. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol. 2009;200: e15-6.
8. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117:497-504.
9. Bansal N, Hoffman M. Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab. Gynecol Oncol. 2011;120:313-4.
10. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140-4. (Pubitemid 44056265)
11. S. Janczar, JS Graham, AJW Paige, H Gabra. Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Rev Obstet. Gynecol. 2009;4:133-47.
12. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.
13. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96-106. (Pubitemid 350267242)
14. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011;29: LBA5006.
15. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16: 1324-30.
16. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424-7.
17. Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. "IMO"- intraoperative mapping of ovarian cancer. Zentralbl Gynakol. 2003;125:129-35. (Pubitemid 37047280)
18. Adhesion Scoring Group, Improvement of interobserver reproducibility of adhesion scoring systems. Fertil Steril. 1994;62: 984-8.
19. Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, et al. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum. 2005;48: 1130-9. (Pubitemid 40897855)
20. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987:156:263-4.
21. Pietzner K, Schmuck RB, Fotopoulou C, Gellermann J, Ismaeel F, Cho CH, et al. Long term combination treatment with bevacizumab, pegylated liposomal Doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature. Anticancer Res. 2011;31: 2675-7.
22. August DA, Serrano D, Poplin E. "Spontaneous" delayed colon and rectal anastomotic complications associated with Bevacizumab therapy. J Surg Oncol. 2008;97:180-5. (Pubitemid 351169051)
23. Wolf I, Urban D, Pfeffer R, Catane R, Aderka D. High incidence of fistula formation during bevacizumab treatment in rectal cancer patients. Acta Oncol. 2007;46:550-3. (Pubitemid 46752251)
24. Adenis A, Vanseymortier L, Foissey D, Colombel JF. Bevacizumab and postponed suture leakages after surgery for ulceration cancer. Gut. 2007;56:734. (Pubitemid 46662946)
25. Ley EJ, Vukasin P, Kaiser AM, Ault G, Beart RW. Delayed rectovaginal fistula: a potential complication of bevacizumab (Avastin). Dis Colon Rectum. 2007;50:930. (Pubitemid 46870455)
26. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105:3-6. (Pubitemid 46441477)
27. Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, dos Santos LA, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2010;116:335-9.
28. Sánchez-Muñoz A, Mendiola C, Pérez-Ruiz E, Rodríguez-Sánchez CA, Jurado JM, Alonso-Carrión L, et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology. 2010;79:98-104.
29. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107: 326-30. (Pubitemid 47575735)
30. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19: 577-82. (Pubitemid 351325682)
31. Khasraw M, Holodny A, Goldlust SA, Deangelis LM. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. 2011 May 4 [Epub ahead of print].
32. Burkart CM, Grisel JJ, Hom DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008;118:1539-41.
33. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010;118:47-51.
34. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011;120:464-9.
35. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107:118-23. (Pubitemid 47464553)
36. Basbug M, Bulbuller N, Camci C, Ayten R, Aygen E, Ozercan IH, et al. The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study. Gastroenterol Res Pract. 2011;2011:578691 [Epub June 28 2011].
37. Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122:233-7.
38. O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:269-72.
39. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117:152-8.
40. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-9.
41. Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2009;115:396-400.
42. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6. Erratum in: J Clin Oncol. 2008;26:1773. (Pubitemid 350232248)
43. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-71. (Pubitemid 350237599)
44. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102:134-9. (Pubitemid 44056263)